Qiagen (NYSE:QGEN) Releases Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.500- for the period, compared to the consensus estimate of 0.500. The company issued revenue guidance of $472.8 million-, compared to the consensus revenue estimate of $477.5 million. Qiagen also updated its FY 2025 guidance to 2.280- EPS.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price target on the stock. in a report on Thursday, October 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price objective (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.07.

Qiagen Stock Down 3.9 %

QGEN traded down $1.71 on Thursday, reaching $42.09. 684,259 shares of the company traded hands, compared to its average volume of 1,139,865. The company has a market cap of $9.34 billion, a price-to-earnings ratio of 104.85, a PEG ratio of 3.10 and a beta of 0.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The stock’s 50 day moving average price is $43.80 and its 200-day moving average price is $43.26. Qiagen has a 52-week low of $40.15 and a 52-week high of $49.30.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. On average, sell-side analysts expect that Qiagen will post 2.23 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.